THE ARISING · Longevity & Healthspan
Phase III Trial of Inhaled Cromolyn Plus Ibuprofen Fails in Early Alzheimer's
A large trial of a drug pair built around ibuprofen, a common antiinflammatory painkiller, did not slow decline in people with early Alzheimer's disease.
The study was a Phase III randomised, double-blind, placebo-controlled trial, the most rigorous kind of human test for a treatment. It was published in 2026 in the Journal of Alzheimer's Disease. It enrolled 619 people with early Alzheimer's. The treatment, called ALZT-OP1, combines two drugs: inhaled cromolyn (17.1 mg) and oral ibuprofen (10 mg). Both act on inflammation. The idea is that inflammation in the brain may contribute to Alzheimer's. The trial tested whether calming it could help.
Participants had early disease. This was defined by a low level of amyloid-β 42 in the fluid around the brain and spinal cord, and a Clinical Dementia Rating-Global score of 0.5. They were assigned at random, in equal numbers, to one of four groups: cromolyn alone, ibuprofen alone, both drugs together, or placebo. Treatment lasted 72 weeks.
The main measure was change in the Clinical Dementia Rating-Sum of Boxes, a score of how much memory and daily function have declined. The trial asked whether the combination beat each single drug. Results covered 594 people in the modified intent-to-treat analysis.
It did not. The combination was not significantly different from cromolyn alone (difference 0.16, 95% CI −0.58 to 0.90; p = 0.675). It was also not significantly different from ibuprofen alone (difference 0.40, 95% CI −0.32 to 1.13; p = 0.276). The primary endpoint was not met. In the authors' words, ALZT-OP1 did not demonstrate efficacy in an unselected early Alzheimer's population.
The researchers also looked at subgroups, including people who carry the APOE4 gene variant, a known genetic risk factor for Alzheimer's. Among people without APOE4, those on the combination did numerically better than those on placebo (least-squares mean difference −0.96; 95% CI −2.00 to 0.08; p = 0.069). That result was not statistically significant. It came from an exploratory analysis, so it cannot be read as a benefit. The authors say it warrants testing in a trial that sorts people by genotype.
The drug was safe and well tolerated over 72 weeks. Whether a genotype-stratified trial is run to test the signal in people without APOE4.